Supplementary Figure S3 from [&lt;sup&gt;89&lt;/sup&gt;Zr]Zr-DFO-girentuximab and [&lt;sup&gt;18&lt;/sup&gt;F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma